Path-breaking healthcare drugs of a doctor from Surendranagar, a small town in Saurashtra, have earned patents from the United States Patents and Trademark office for three bioactive drugs.
Dr Mukesh Shukla — who prefers to be called a research scientist — has developed three drugs from plant-based extracts or from bio-active compositions. The drugs are for HIV+ AIDS, liver dysfunction jaundice, ischemic heart disease-anti-oxidant for patients suffering from high cholesterol.
While the US Patent has been granted for liver dysfunction jaundice and anti oxidant on April 30, the anti-HIV drug was granted patent on April 2, said Shukla.
The doctor achieved success in developing the drugs following a hard work of around eight years, clinical trials on mice and 81 human clinical trials and investment of Rs 1.27 crore. Speaking todna, he has developed bioactive composition from Curcurmin-principal curcuminoid of Indian spice turmeric, Cyprus Rotus, Solanum nigrum, Tulsi or Ocinum acid to manufacture various drugs.
While the drugs boost immunity in HIV-positive patients, it removes cholesterol from heart artery and blockage, said Shukla.
"I have always believed that millions of people in the world suffer from these diseases and effective drugs should be easily available and at affordable rates. Since 1981, 25 million people have died of AIDS-related illness and 65 million have been infected with HIV worldwide," said Shukla.
"In 2006 alone, 4.3 million new infections were recorded, alongside 2.9 million AIDS-related deaths, more than in any previous year. Also, there are limited therapies available for the disease. And, this is one of the reasons I chose to work for the development of effective drugs for such diseases," said Shukla, an alumnus of Sheth CN Vidyalaya in Ahmedabad.
The doctor has also filed patents for an anti-malaria drug in India and the publication of which was accepted by the Government of India. He has assigned the rights for the manufacturing of the patented drugs for HIV-AIDS to one company and is looking for more company partners to launch other drugs for the benefit of the patients.
Shukla shifted his base to the US as he was encouraged to pursue research to invent effective drugs for diseases like HIV+ and others. He, however, returned to India about 15 years ago and kept shuttling between India and the US to complete his research.
Dr Mukesh Shukla — who prefers to be called a research scientist — has developed three drugs from plant-based extracts or from bio-active compositions. The drugs are for HIV+ AIDS, liver dysfunction jaundice, ischemic heart disease-anti-oxidant for patients suffering from high cholesterol.
While the US Patent has been granted for liver dysfunction jaundice and anti oxidant on April 30, the anti-HIV drug was granted patent on April 2, said Shukla.
The doctor achieved success in developing the drugs following a hard work of around eight years, clinical trials on mice and 81 human clinical trials and investment of Rs 1.27 crore. Speaking todna, he has developed bioactive composition from Curcurmin-principal curcuminoid of Indian spice turmeric, Cyprus Rotus, Solanum nigrum, Tulsi or Ocinum acid to manufacture various drugs.
While the drugs boost immunity in HIV-positive patients, it removes cholesterol from heart artery and blockage, said Shukla.
"I have always believed that millions of people in the world suffer from these diseases and effective drugs should be easily available and at affordable rates. Since 1981, 25 million people have died of AIDS-related illness and 65 million have been infected with HIV worldwide," said Shukla.
"In 2006 alone, 4.3 million new infections were recorded, alongside 2.9 million AIDS-related deaths, more than in any previous year. Also, there are limited therapies available for the disease. And, this is one of the reasons I chose to work for the development of effective drugs for such diseases," said Shukla, an alumnus of Sheth CN Vidyalaya in Ahmedabad.
The doctor has also filed patents for an anti-malaria drug in India and the publication of which was accepted by the Government of India. He has assigned the rights for the manufacturing of the patented drugs for HIV-AIDS to one company and is looking for more company partners to launch other drugs for the benefit of the patients.
Shukla shifted his base to the US as he was encouraged to pursue research to invent effective drugs for diseases like HIV+ and others. He, however, returned to India about 15 years ago and kept shuttling between India and the US to complete his research.
No comments:
Post a Comment